SOTIO Biotech has announced it will be exercising its option with Synaffix BV to develop two bispecific antibody-drug conjugate (ADC) programs. The bispecific antibody candidates were identified by SOTIO’s research team and will now be developed under SOTIO’s license and option agreement with Synaffix, which enables SOTIO to combine its proprietary antibodies with Synaffix’s GlycoConnect®, HydraSpace®, and potent linker-payload platforms to research, develop, manufacture, and commercialize ADC products. Peter Van de Sande, Head of Synaffix, commented: “We are pleased that SOTIO, recognizing the versatility and robustness of our clinically validated platform, has chosen to expand its use of our ADC technology to two additional targets. Bispecific ADCs are a key part of our offering, and our technology is primed to support this next stage of innovation in targeted cancer therapeutics. We look forward to seeing these promising candidates advance toward the clinic.” #ADCs #oncology #drugdevelopment #biotech
Today, we announced the expansion of our ADC pipeline — and our collaboration with Synaffix BV — to develop two novel bispecific candidates. SOT112 and SOT113 are our first investigational bispecific ADCs for #cancer treatment. These candidates offer exciting potential for treating solid tumors, with SOT112 targeting multiple cancer types and SOT113 focusing on precision treatment for #prostatecancer. Read more in today’s release: https://lnkd.in/eH6h5J6j #DrugDiscovery #ADC #Biotechnology #jsmePPF
Congratulations! Further recognition of Synaffix BV's clinically validated ADC platform technology 👏